Egetis Therapeutics ABPDPHF 24 Days Payable is 150.88 as of Mar. 2026, which is 239% above its 10-year median of 44.46. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 708 Biotechnology companies, Egetis Therapeutics AB ranks better than 58.47% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDPHF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Egetis Therapeutics AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB (PDPHF) has a Days Payable of 150.88 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Egetis Therapeutics AB and its competitors. This is 239% above median its historical median of 44.46. Over the past decade, Egetis Therapeutics AB's Days Payable has ranged from 25.25 to 855.86. According to the industry distribution chart, Egetis Therapeutics AB ranks #294 out of 708 companies in the Biotechnology industry, placing it in the top 41.5%.
Is Egetis Therapeutics AB's Days Payable too high?
Egetis Therapeutics AB's current Days Payable of 150.88 is 239% above median its 10-year median of 44.46. Over the past 10 years, this metric has ranged from a low of 25.25 to a high of 855.86. The Biotechnology industry median Days Payable is 113.56. Egetis Therapeutics AB's value of 150.88 is 32.9% above this industry median. Based on the distribution chart, Egetis Therapeutics AB ranks #294 out of 708 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #294 out of 708 companies for Days Payable. This puts Egetis Therapeutics AB in the upper half of its industry. The industry median Days Payable is 113.56. Egetis Therapeutics AB's value of 150.88 is 32.9% above this benchmark. Historically, Egetis Therapeutics AB's own Days Payable has ranged from 25.25 to 855.86 over the past decade. While the company's 10-year median is 44.46 vs. the industry median of 113.56, Egetis Therapeutics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egetis Therapeutics AB's current Days Payable of 150.88 is 32.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current Days Payable is 150.88, which is 239% above median its own 10-year median of 44.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current Days Payable is 150.88, which is 239% above median its 10-year median of 44.46 and 32.9% above the Biotechnology industry median of 113.56. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current Days Payable is 150.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued.
The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64.
GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.
Key valuation signals for PDPHF:
Days Payable: 150.88 (239% above median its 10-year median of 44.46)
GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
Industry Position: 32.9% above the Biotechnology median (#294 of 708)
No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score
Get the complete analysis for PDPHF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDPHF has been successfully added to your 
